Pa. Bio Cos. End Gene Therapy Row In Deal Worth Up To $75M
Pittsburgh biotech company PeriphaGen Inc. reached a settlement to end litigation alleging its former lab partner, Krystal Biotech Inc., copied its gene therapy technology, with the deal worth at least $25...To view the full article, register now.
Already a subscriber? Click here to view full article